Establishing a neoadjuvant platform for developing targeted agents: Degarelix prior to prostatectomy for patients with intermediate- and high-risk prostate cancer. A phase I/II study of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback